138 related articles for article (PubMed ID: 30017858)
1. Tetrabenazine, a vesicular monoamine transporter-2 inhibitor, attenuates morphine-induced hyperlocomotion in mice through alteration of dopamine and 5-hydroxytryptamine turnover in the cerebral cortex.
Kitanaka N; Kitanaka J; Hall FS; Kandori T; Murakami A; Muratani K; Nakano T; Uhl GR; Takemura M
Pharmacol Biochem Behav; 2018 Sep; 172():9-16. PubMed ID: 30017858
[TBL] [Abstract][Full Text] [Related]
2. Tetrabenazine inhibition of monoamine uptake and methamphetamine behavioral effects: locomotor activity, drug discrimination and self-administration.
Meyer AC; Horton DB; Neugebauer NM; Wooters TE; Nickell JR; Dwoskin LP; Bardo MT
Neuropharmacology; 2011 Sep; 61(4):849-56. PubMed ID: 21669212
[TBL] [Abstract][Full Text] [Related]
3. The vesicular monoamine transporter (VMAT-2) inhibitor tetrabenazine induces tremulous jaw movements in rodents: implications for pharmacological models of parkinsonian tremor.
Podurgiel SJ; Nunes EJ; Yohn SE; Barber J; Thompson A; Milligan M; Lee CA; López-Cruz L; Pardo M; Valverde O; Lendent C; Baqi Y; Müller CE; Correa M; Salamone JD
Neuroscience; 2013 Oct; 250():507-19. PubMed ID: 23867769
[TBL] [Abstract][Full Text] [Related]
4. Effects of tetrabenazine on methamphetamine-induced hyperactivity in mice are dependent on order and time-course of administration.
Kuribara H
Pharmacol Biochem Behav; 1997 Jan; 56(1):9-14. PubMed ID: 8981603
[TBL] [Abstract][Full Text] [Related]
5. Metoprine, a histamine N-methyltransferase inhibitor, attenuates methamphetamine-induced hyperlocomotion via activation of histaminergic neurotransmission in mice.
Kitanaka N; Hall FS; Kobori S; Kushihara S; Oyama H; Sasaoka Y; Takechi M; Tanaka KI; Tomita K; Igarashi K; Nishiyama N; Sato T; Uhl GR; Kitanaka J
Pharmacol Biochem Behav; 2021 Oct; 209():173257. PubMed ID: 34418452
[TBL] [Abstract][Full Text] [Related]
6. The MAO-B inhibitor deprenyl reduces the oral tremor and the dopamine depletion induced by the VMAT-2 inhibitor tetrabenazine.
Podurgiel SJ; Yohn SE; Dortche K; Correa M; Salamone JD
Behav Brain Res; 2016 Feb; 298(Pt B):188-91. PubMed ID: 26590367
[TBL] [Abstract][Full Text] [Related]
7. Modification of morphine-induced hyperlocomotion and antinociception in mice by clorgyline, a monoamine oxidase-A inhibitor.
Kitanaka N; Kitanaka J; Takemura M
Neurochem Res; 2006 Jun; 31(6):829-37. PubMed ID: 16794857
[TBL] [Abstract][Full Text] [Related]
8. The dopamine depleting agent tetrabenazine alters effort-related decision making as assessed by mouse touchscreen procedures.
Yang JH; Presby RE; Rotolo RA; Quiles T; Okifo K; Zorda E; Fitch RH; Correa M; Salamone JD
Psychopharmacology (Berl); 2020 Sep; 237(9):2845-2854. PubMed ID: 32561947
[TBL] [Abstract][Full Text] [Related]
9. Role of vesicular monoamine transporter type 2 in rodent insulin secretion and glucose metabolism revealed by its specific antagonist tetrabenazine.
Raffo A; Hancock K; Polito T; Xie Y; Andan G; Witkowski P; Hardy M; Barba P; Ferrara C; Maffei A; Freeby M; Goland R; Leibel RL; Sweet IR; Harris PE
J Endocrinol; 2008 Jul; 198(1):41-9. PubMed ID: 18577569
[TBL] [Abstract][Full Text] [Related]
10. Not All Antidepressants Are Created Equal: Differential Effects of Monoamine Uptake Inhibitors on Effort-Related Choice Behavior.
Yohn SE; Collins SL; Contreras-Mora HM; Errante EL; Rowland MA; Correa M; Salamone JD
Neuropsychopharmacology; 2016 Feb; 41(3):686-94. PubMed ID: 26105139
[TBL] [Abstract][Full Text] [Related]
11. Dopamine depletion shifts behavior from activity based reinforcers to more sedentary ones and adenosine receptor antagonism reverses that shift: Relation to ventral striatum DARPP32 phosphorylation patterns.
López-Cruz L; San Miguel N; Carratalá-Ros C; Monferrer L; Salamone JD; Correa M
Neuropharmacology; 2018 Aug; 138():349-359. PubMed ID: 29408363
[TBL] [Abstract][Full Text] [Related]
12. Apparent opposite effects of tetrabenazine and reserpine on the toxic effects of 1-methyl-4-phenylpyridinium or 6-hydroxydopamine on nigro-striatal dopaminergic neurons.
Cleren C; Naudin B; Costentin J
Brain Res; 2003 Nov; 989(2):187-95. PubMed ID: 14556940
[TBL] [Abstract][Full Text] [Related]
13. Identification of conformationally sensitive residues essential for inhibition of vesicular monoamine transport by the noncompetitive inhibitor tetrabenazine.
Ugolev Y; Segal T; Yaffe D; Gros Y; Schuldiner S
J Biol Chem; 2013 Nov; 288(45):32160-32171. PubMed ID: 24062308
[TBL] [Abstract][Full Text] [Related]
14. GZ-793A, a lobelane analog, interacts with the vesicular monoamine transporter-2 to inhibit the effect of methamphetamine.
Horton DB; Nickell JR; Zheng G; Crooks PA; Dwoskin LP
J Neurochem; 2013 Oct; 127(2):177-86. PubMed ID: 23875622
[TBL] [Abstract][Full Text] [Related]
15. Effect of tetrabenazine on the striatal uptake of exogenous L-DOPA in vivo: a PET study in young and aged rhesus monkeys.
DeJesus OT; Shelton SE; Roberts AD; Nickles RJ; Holden JE
Synapse; 2002 Jun; 44(4):246-51. PubMed ID: 11984859
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of methamphetamine-induced hyperlocomotion in mice by clorgyline, a monoamine oxidase-a inhibitor, through alteration of the 5-hydroxytriptamine turnover in the striatum.
Kitanaka N; Kitanaka J; Takemura M
Neuroscience; 2005; 130(2):295-308. PubMed ID: 15664686
[TBL] [Abstract][Full Text] [Related]
17. Tetrabenazine-induced depletion of brain monoamines: characterization and interaction with selected antidepressants.
Pettibone DJ; Totaro JA; Pflueger AB
Eur J Pharmacol; 1984 Jul; 102(3-4):425-30. PubMed ID: 6489435
[TBL] [Abstract][Full Text] [Related]
18. Tetrabenazine Facilitates Exocytosis by Enhancing Calcium-Induced Calcium Release through Ryanodine Receptors.
de Pascual R; Álvarez-Ortego N; de Los Ríos C; Jacob-Mazariego G; García AG
J Pharmacol Exp Ther; 2019 Oct; 371(1):219-230. PubMed ID: 31209099
[TBL] [Abstract][Full Text] [Related]
19. Tetrabenazine, a monoamine-depleting drug used in the treatment of hyperkinetic movement disorders.
Guay DR
Am J Geriatr Pharmacother; 2010 Aug; 8(4):331-73. PubMed ID: 20869622
[TBL] [Abstract][Full Text] [Related]
20. Effects of adrenal medulla graft on recovery of GABAergic and dopaminergic neuron deficits in mice: behavioural, pharmacological and immunohistochemical study.
Jousselin-Hosaja M; Tobin C; Venault P; Joubert C; Chapouthier G
Behav Brain Res; 2003 Mar; 140(1-2):185-93. PubMed ID: 12644291
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
